Polymorphisms in the promoter region of ESR2 gene and breast cancer susceptibility

Journal of Steroid Biochemistry and Molecular Biology

Volumn 114, Issue 3-5, 2009, Pages 207-211

  Treeck, Oliver ^a   Elemenler, Esma ^a   Kriener, Christina ^a   Horn, Felicitas ^a   Springwald, Anette ^a   Hartmann, Arndt ^a   Ortmann, Olaf ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Breast cancer; Case control study; Estrogen receptor beta; Single nucleotide polymorphism

Indexed keywords

ESTROGEN RECEPTOR; ESTROGEN RECEPTOR 2; ESTROGEN RECEPTOR BETA; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; AMINO ACID SEQUENCE; ARTICLE; BREAST CANCER; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; SINGLE NUCLEOTIDE POLYMORPHISM;

BREAST NEOPLASMS; CASE-CONTROL STUDIES; DNA MUTATIONAL ANALYSIS; ESTROGEN RECEPTOR BETA; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MIDDLE AGED; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC;

TETRA;

EID: 63149197183     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2009.02.012     Document Type: Article

References (53)

1. Ali S., and Coombes R.C. Endocrine-responsive breast cancer and strategies for combating resistance. Nat. Rev. Cancer 2 (2002) 101-112
2. Kuiper G.G., Enmark E., Pelto-Huikko M., Nilsson S., and Gustafsson J.A. Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 5925-5930
3. Leygue E., Dotzlaw H., Watson P., and Murphy L. Altered estrogen receptor alpha and beta mRNA expression during human breast tumorigenesis. Cancer Res. 58 (1998) 3197-3201
4. Jarvinen T., Pelto-Huikko M., Holli K., and Isola J. Estrogen receptor beta is coexpressed with ER alpha and PR and associated with nodal status grade and proliferation rate in breast cancer. Am. J. Pathol. 156 (2000) 29-35
5. Forster C., Makela S., Warri A., Kietz S., Becker D., Hultenby K., Warner M., and Gustafsson J. Involvement of estrogen receptor b in terminal differentiation of mammary gland epithelium. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 15578-15583
6. Hall J., and McDonnell D. The estrogen receptor betaisoform (ER beta) of the human estrogen receptor modulates ER alpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 140 (1999) 5566-5578
7. Weihua Z., Saji S., Makinen S., Cheng G., Jensen E., Warner M., and Gustaffson J.A. Estrogen receptor (ER) b a modulator of ER a in the uterus. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 5936-5941
8. Peng B., Lu B., Leygue E., and Murphy L. Putative functional characteristics of human estrogen receptor-beta isoforms. J. Mol. Endocrinol. 30 (2003) 13-29
9. Roger P., Sahla M., Makela S., Gustafsson J.A., Baldet P., and Rochefort H. Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res. 61 (2001) 2537-2541
10. Skliris G., Munot K., Bell S., Carder P., Lane S., Horgan K., Lansdown M., Parkes A., Hanby A., Markham A., and Speirs V. Reduced expression of oestrogen receptor beta in invasive breast cancer and its re-expression using DNA methyltransferase inhibitors in a cell line model. J. Pathol. 201 (2003) 213-220
11. Dotzlaw H., Leygue E., Watson P., and Murphy L. Estrogen receptor-b messenger RNA expression in human breast tumor biopsies: relationship to steroid receptor status and regulation by progestins. Cancer Res. 59 (1999) 529-532
12. Speirs V. Oestrogen receptor beta in breast cancer: good bad or still too early to tell?. J. Pathol. 197 (2002) 143-147
13. Fuqua S., Schiff R., Parra I., Friedrichs W., Su J., McKee D., Slentz-Kesler K., Moore L., Willson T., and Moore J. Expression of wild-type estrogen receptor beta and variant isoforms in human breast cancer. Cancer Res. 59 (1999) 5425-5428
14. Saji S., Omoto Y., Shimizu C., Warner M., Hayashi Y., Horiguchi S., Watanabe T., Hayashi S., and Gustafsson J. Expression of estrogen receptor (ER) (beta)cx protein in ER(alpha)-positive breast cancer: specific correlation with progesterone receptor. Cancer Res. 62 (2002) 4849-4853
15. Saji S., Omoto Y., Shimizu C., Horiguchi S., Watanabe T., Funata N., Hayash S., Gustafsson J., and Toi M. A Clinical impact of assay of estrogen receptor beta cx in breast cancer. Breast Cancer Res. Treat. 9 (2002) 303-307
16. Erfani N., Razmkhah M., Talei A.R., Pezeshki A.M., Doroudchi M., Monabati A., Ghaderi A., and Cytotoxic. T lymphocyte antigen-4 promoter variants in breast cancer. Cancer Genet. Cytogenet. 165 (2006) 114-120
17. Harendza S., Lovett D.H., Panzer U., Lukacs Z., Kuhnl P., and Stahl R.A. Linked common polymorphisms in the gelatinase a promoter are associated with diminished transcriptional response to estrogen and genetic fitness. J. Biol. Chem. 278 (2003) 20490-20499
18. Stevens A., Soden J., Brenchley P.E., Ralph S., and Ray D.W. Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res. 63 (2003) 812-816
19. Yang Q., Nakamura M., Nakamura Y., Yoshimura G., Suzuma T., Umemura T., Tamaki T., Mori I., Sakurai T., and Kakudo K. Correlation of prostate-specific antigen promoter polymorphisms with clinicopathological characteristics in breast cancer. Anticancer Res. 22 (2002) 1825-1828
20. Alvarez-Millan J.J., Bocos C., Ferri-n V., Lucas A.R., Ruibal A., and Schneider J. PAI-1 promoter polymorphism modulates uPA-PAI complex accumulation by breast cancer cells. Oncology 62 (2002) 286-290
21. Guillemette C., Millikan R.C., Newman B., and Housman D.E. Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and association with breast cancer among African Americans. Cancer Res. 60 (2000) 950-956
22. Bergman-Jungeström M., Gentile M., Lundin A.C., and Wingren S. Association between CYP17 gene polymorphism and risk of breast cancer in young women. Int. J. Cancer 84 (1999) 350-353
23. Greenlee H., Chen Y., Kabat G.C., Wang Q., Kibriya M.G., Gurvich I., Sepkovic D.W., Bradlow H.L., Senie R.T., Santella R.M., and Ahsan H. Variants in estrogen metabolism and biosynthesis genes and urinary estrogen metabolites in women with a family history of breast cancer. Breast Cancer Res. Treat. 102 (2007) 111-117
24. Abrahamson P.E., Tworoger S.S., Aiello E.J., Bernstein L., Ulrich C.M., Gilliland F.D., Stanczyk F.Z., Baumgartner R., Baumgartner K., Sorensen B., Ballard-Barbash R., and McTiernan A. Associations between the CYP17, CYPIB1 COMT and SHBG polymorphisms and serum sex hormones in post-menopausal breast cancer survivors. Breast Cancer Res. Treat. 105 (2007) 45-54
25. Feigelson H.S., Cox D.G., Cann H.M., Wacholder S., Kaaks R., Henderson B.E., et al. Haplotype analysis of the HSD17B1 gene and risk of breast cancer: a comprehensive approach to multicenter analyses of prospective cohort studies. Cancer Res. 66 (2006) 2468-2475
26. Crooke P.S., Ritchie M.D., Hachey D.L., Dawling S., Roodi N., Parl F.F., and Estrogens. Enzyme variants, and breast cancer: a risk model. Cancer Epidemiol. Biomarkers Prev. 15 (2006) 1620-1629
27. Silva S.N., Cabral M.N., Bezerra de Castro G., Pires M., Azevedo A.P., Manita I., Pina J.E., Rueff J., and Gaspar J. Breast cancer risk and polymorphisms in genes involved in metabolism of estrogens (CYP17, HSD17beta1 COMT and MnSOD): possible protective role of MnSOD gene polymorphism Val/Ala and Ala/Ala in women that never breast fed. Oncol. Rep. 16 (2006) 781-788
28. Folkerd E.J., Martin L.A., Kendall A., and Dowsett M. The relationship between factors affecting endogenous oestradiol levels in postmenopausal women and breast cancer. J. Steroid Biochem. Mol. Biol. 102 (2006) 250-255
29. Lurie G., Maskarinec G., Kaaks R., Stanczyk F.Z., and Le Marchand L. Association of genetic polymorphisms with serum estrogens measured multiple times during a 2-year period in premenopausal women. Cancer Epidemiol. Biomarkers Prev. 14 (2005) 1521-1527
30. Chacko P., Rajan B., Mathew B.S., Joseph T., and Pillai M.R. CYP17 and SULT1A1 gene polymorphisms in Indian breast cancer. Breast Cancer 11 (2004) 380-388
31. Zheng S.L., Zheng W., Chang B.L., Shu X.O., Cai Q., Yu H., Dai Q., Xu J., and Gao Y.T. Joint effect of estrogen receptor beta sequence variants and endogenous estrogen exposure on breast cancer risk in Chinese women. Cancer Res. 63 (2003) 7624-7629
32. Schuit S.C., de Jong F.H., Stolk L., Koek W.N., van Meurs J.B., Schoofs M.W., Zillikens M.C., Hofman A., van Leeuwen J.P., Pols H.A., and Uitterlinden A.G. Estrogen receptor alpha gene polymorphisms are associated with estradiol levels in postmenopausal women. Eur. J. Endocrinol. 153 (2005) 327-334
33. Tempfer C.B., Schneeberger C., and Huber J.C. Applications of polymorphisms and pharmacogenomics in obstetrics and gynecology. Pharmacogenomics 5 (2004) 57-65
34. Gold B., Kalush F., Bergeron J., Scott K., Mitra N., Wilson K., Ellis N., Huang H., Chen M., and Lippert R. Estrogen receptor genotypes and haplotypes associated with breast cancer risk. Cancer Res. 64 (2004) 8891-8900
35. Kitawaki J., Kado N., Ishihara H., Koshiba H., Kitaoka Y., and Honjo H:. Endometriosis. the pathophysiology as an estrogen-dependent disease. J. Steroid Biochem. Mol. Biol. 83 (2002) 149-155
36. Ye S., Dhillon S., Ke Xiayi, and Collins A.R. Day IN. An efficient procedure for genotyping single nucleotide polymorphisms. Nucleic Acids Res. 29 (2001) E88-E98
37. Cribb A.E., Knight M.J., Dryer D., Guernsey J., Hender K., Tesch M., and Saleh T.M. Role of polymorphic human cytochrome P450 enzymes in estrone oxidation. Cancer Epidemiol. Biomarkers Prev. 15 (2006) 551-558
38. Setiawan V.W., Hankinson S.E., Colditz G.A., Hunter D.J., and Vivo I.D. Estrogen receptor beta (ESR2) polymorphisms and endometrial cancer (United States). Cancer Causes Control 15 (2004) 627-633
39. Sundarrajan C., Liao W.X., Roy A.C., and Ng S.C. Association between estrogen receptor-beta gene polymorphisms and ovulatory dysfunctions in patients with menstrual disorders. J. Clin. Endocrinol. Metab. 86 (2001) 135-139
40. Ogawa S., Hosoi T., Shiraki M., Orimo H., Emi M., Muramatsu M., Ouchi Y., and Inoue S. Association of estrogen receptor beta gene polymorphism with bone mineral density. Biochem. Biophys. Res. Commun. 269 (2000) 537-541
41. Rosenkranz K., Hinney A., Ziegler A., Hermann H., Fichter M., Mayer H., Siegfried W., Young J.K., Remschmidt H., and Hebebrand J. Systematic mutation screening of the estrogen receptor beta gene in probands of different weight extremes: identification of several genetic variants. J. Clin. Endocrinol. Metab. 83 (1998) 4524-4527
42. Forsti A., Zhao C., Israelsson E., Dahlman-Wright K., Gustafsson J.A., and Hemminki K. Polymorphisms in the estrogen receptor beta gene and risk of breast cancer: no association. Breast Cancer Res. Treat. 79 (2003) 409-413
43. Maguire P., Margolin S., Skoglund J., Sun X.F., Gustafsson J.A., BØrresen-Dale A.L., and Lindblom A. Estrogen receptor beta (ESR2) polymorphisms in familial and sporadic breast cancer. Breast Cancer Res. Treat. 94 (2005) 145-152
44. Gao J., Shan G., Sun B., Thompson P.J., and Gao X. Association between polymorphism of tumour necrosis factor alpha-308 gene promoter and asthma: a meta-analysis. Thorax 61 (2006) 466-471
45. Capurso C., Solfrizzi V., D'Introno A., Colacicco A.M., Capurso S.A., Capurso A., and Panza F. Interleukin 6-174 G/C promoter gene polymorphism and sporadic Alzheimer's disease: geographic allele and genotype variations in Europe. Exp. Gerontol. 39 (2004) 1567-1573
46. Thellenberg-Karlsson C., Lindström S., Malmer B., Wiklund F., Augustsson-Balter K., Adami H.O., Stattin P., Nilsson M., Dahlman-Wright K., Gustafsson J.A., and Gronberg H. Estrogen receptor beta polymorphism is associated with prostate cancer risk. Clin. Cancer Res. 12 (2006) 1936-1941
47. Beleza-Meireles A., Kockum I., Lundberg F., Söderhäll C., and Nordenskjöld A. Risk factors for hypospadias in the estrogen receptor 2 gene. J. Clin. Endocrinol. Metab. 92 (2007) 3712-3718
48. Hunter D.J., Kraft P., Jacobs K.B., Cox D.G., Yeager M., Hankinson S.E., et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat. Genet. 39 7 (2007) 870-874
49. Murillo-Ortiz B., De la Veja H., Castillo-Medina S., Malacara J., and Benitez-Bribiesca L. Telomerase activity, estrogen receptors (alpha, beta) Bcl-2 expression in human breast cancer and treatment response. BMC Cancer (2006) 206
50. Shaw J.A., Udokang K., Mosquera J.M., Chauhan H., Jones J.L., and Walker R.A. Oestrogen receptors alpha and beta differ in normal human breast and breast carcinomas. J. Pathol. 198 (2002) 450-457
51. Hayashi S.I., Eguchi H., Tanimoto K., et al. The expression and function of estrogen receptor alpha and beta in human breast cancer and its clinical application. Endocr. Relat. Cancer 10 (2003) 193-202
52. Poola I., Abraham J., and Liu A. Estrogen receptor beta splice variant mRNAs are differentially altered during breast carcinogenesis. J. Steroid Biochem. Mol. Biol. 82 (2002) 169-179
53. Speirs V., and Kerin M.J. Prognostic significance of oestrogen receptor beta in breast cancer. Br. J. Surg. 87 (2000) 405-409